SHARPE
Reported results
- GAAP reported net revenues increased 5.3% to $4.733 billion during the third quarter of 2026 compared to $4.495 billion in the third quarter of 2025.
- GAAP reported net income attributable to UHS was $308.7 million, or $5.22 per diluted share, in Q3 2026 compared to $373.0 million, or $5.86 per diluted share, in Q3 2025.
- Non-GAAP EBITDA net of NCI was $640.4 million for the third quarter of 2026 compared to $684.2 million for the third quarter of 2025.
- Non-GAAP Adjusted EBITDA net of NCI was $624.6 million for the third quarter of 2026 compared to $670.6 million for the third quarter of 2025.
- For the nine months ended September 30, 2026, non-GAAP adjusted net income attributable to UHS was $1.014 billion, or $16.83 per diluted share, compared to $1.030 billion, or $15.87 per diluted share, in the comparable 2025 period.
Notes
Prior year amounts related to certain facilities previously included in Behavioral Health Care Services’ results have been reclassified into Acute Care Hospital Services’ results as of January 1, 2025 to conform with current year presentation.
Price and volatility reaction
The stock moved -2.9% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -9.4 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 177.32 | 2026-10-27 |
| Close after release | 172.18 | 2026-10-28 |
| Realised move | -2.9% | close to close |
| 30d ATM IV change | -9.4 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-27 (8-K, Item 2.02). Read the original filing on sec.gov.